logo-loader
viewZynerba Pharmaceuticals

Zynerba wins US patent for treatment of autism spectrum disorder with purified CBD

The patent is part of its growing IP portfolio covering its flagship transdermal cannabidiol product candidate -- Zygel CBD gel

Zynerba Pharmaceuticals - Zynerba Pharmaceuticals Incwins US patent for treatment of autism spectrum disorder with purified cannabidiol (CBD)
Zynerba, based in Devon, Pennsylvania, expects to report top-line data from the trial in the 2Q of 2020

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Tuesday that it has won a US patent for the treatment of autism spectrum disorder (ASD) with purified cannabidiol (CBD). 

The new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the company's flagship transdermal cannabidiol product candidate -- Zygel CBD gel, according to a statement.  

The patent titled “Treatment of Autism with Cannabidiol” includes claims directed to methods of treating ASD by transdermally administering, via a gel or cream, a therapeutically effective amount of purified CBD.

READ: Zynerba wins US patent for treatment of Fragile X syndrome with its Zygel CBD gel

This patent follows the previously announced issuance of a related patent granted by US Patent and Trademark Office to treat ASD by transdermally administering, via gel or cream, synthetic cannabidiol.

Zynerba said it has completed enrollment in the open-label Phase 2 BRIGHT study evaluating the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with ASD, with 37 patients enrolled.

The efficacy assessments include the Aberrant Behavior Checklist, Parent Rated Anxiety Scale – Autism Spectrum Disorder, Autism Impact Measure, and Clinical Global Impression – Severity and Improvement.

Zynerba, based in Devon, Pennsylvania, expects to report top-line data from this trial in the second quarter of 2020.

The company’s stock recently traded 11% higher to $5.13 a share in pre-market trading in New York. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Zynerba Pharmaceuticals

Price: 3.47 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $81.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read